Botulinum toxin for vocal fold granuloma: a systematic review and meta-analysis of treatment outcomes and recurrence
European Archives of Oto-Rhino-Laryngology · 2026-07 · 283 (7) · 4199-4217
DOI: 10.1007/s00405-026-10254-4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Archives of Oto-Rhino-Laryngology, online erschienen am 21.05.2026. Verfasst von Ibrahim M Aljohani und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, College of Medicine, Taif University, Taif, Saudi Arabia. Dribrahimaljohani111@gmail.com. Hauptthemen laut MEDLINE: Vocal Cords, Granuloma, Laryngeal, Botulinum Toxins, Type A, Neuromuscular Agents. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To synthesize outcomes after botulinum toxin A (BTX-A) injection for vocal process granuloma (VPG), including remission, recurrence, time to resolution, and safety. METHODS: We pooled 18 studies (n = 1,146 patients; 298 received BTX‑A) reporting clinical outcomes after BTX‑A injection for VPG. Random‑effects meta‑analysis produced pooled event rates with 95% confidence intervals; prespecified subgroup analyses compared primary versus refractory contact granulomas (CG) and intubation‑related granulomas (IG). RESULTS: Overall pooled complete remission after BTX‑A was 87.6% (95% CI 82.6-92.9%); most remissions occurred within 1-3 months. Subgroup pooled complete remission rates were 87.4% (95% CI 81.3-93.9%) for refractory CG, 91.1% (95% CI 79.8-103.9%) for primary CG, and 70.2% (95% CI 57.1-107.2%) for intubation‑related granulomas. Overall pooled Recurrence after initial remission was 6.9% (95% CI 3.1-15.5%); subgroup recurrence estimates were 9.4% for refractory CG, 5.7% for primary CG, and 19.8% for refractory IG. Pooled adverse‑event rates included hoarseness 9.1%, aspiration/choking 29.1%, and breathiness/dysphagia 29.4%; most events resolved within weeks to a few months. Objective voice‑quality measures were infrequently reported. CONCLUSION: BTX‑A injection achieves high short-term remission and low Recurrence in VPG, with mostly transient side effects. It shows good durability in contact granulomas but less so in intubation-related lesions. More randomized studies with validated voice outcomes are needed to determine optimal dosing and long-term effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, College of Medicine, Taif University, Taif, Saudi Arabia. Dribrahimaljohani111@gmail.com.
- Department of Otorhinolaryngology, College of Medicine, Taif University, Taif, Saudi Arabia.
- College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
- Department of Otolaryngology-Head and Neck Surgery, King Abdulaziz Specialist Hospital, Taif, Saudi Arabia.
- Department of Otorhinolaryngology, College of Medicine, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
- General Medicine Program, Batterjee Medical College, Jeddah, Saudi Arabia.
Zitieren
APA
Aljohani, I. M., Al-Juaid, E. M., Abualjamal, R. Y., Baali, M. H., Alotaibi, N. A., Manzoor, A., Ababtain, R. M., Alzyadi, S. M., & Almalki, Z. A. (2026). Botulinum toxin for vocal fold granuloma: a systematic review and meta-analysis of treatment outcomes and recurrence. European Archives of Oto-Rhino-Laryngology, 283(7), 4199-4217. https://doi.org/10.1007/s00405-026-10254-4
Vancouver
Aljohani IM, Al-Juaid EM, Abualjamal RY, Baali MH, Alotaibi NA, Manzoor A, et al. Botulinum toxin for vocal fold granuloma: a systematic review and meta-analysis of treatment outcomes and recurrence. European Archives of Oto-Rhino-Laryngology. 2026;283(7):4199-4217. doi:10.1007/s00405-026-10254-4
BibTeX
@article{Aljohani2026,
author = {Aljohani, Ibrahim M and Al-Juaid, Elaf Mansour and Abualjamal, Rena Y and Baali, Mohammed H and Alotaibi, Nuha Ali and Manzoor, Ameena and Ababtain, Reem Mohammed and Alzyadi, Shahad Mukhlid and Almalki, Zohour Awadh},
title = {Botulinum toxin for vocal fold granuloma: a systematic review and meta-analysis of treatment outcomes and recurrence},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2026},
volume = {283},
number = {7},
pages = {4199--4217},
doi = {10.1007/s00405-026-10254-4}
}
EUVIMED